c-Myc oncoprotein expression and prognosis in patients with carcinoma of the cervix: An n immunohistochemical study

Objective: Evaluation of the prognostic significance of c-Myc expression in carcinoma of the cervix.

Materials and methods: 132 patients with carcinoma of the cervix presenting at the Cancer Institute in Chennai from 1996-1999 were included in the study. All the cases were treated with a radical course of radiotherapy and had a median follow-up of 36 months. Paraffin blocks obtained from the punch biopsies from the tumours were used for immunohistochemistry.

Results: c-Myc nuclear immunoreactivity was observed in 44/132 (33.3%) of tumours. Patients with tumours in Stages 11 B and III B accounted for 112/132 (84.8%) of the cases. Patients with tumours expressing c-Myc nuclear immunoreactivity were found to have more advanced disease; less likely to achieve complete remission (54.5% vs. 78.4%; p < 0.005) and lower disease-free status (52.3% versus 73.8%; p < 0.014). The poor prognostic feature of c-Myc nuclear immunoreactivity was seen in both stage II B (52.9% vs. 76.3%) and stage III B (38.1% vs. 69.4%; p < 0.025).

Conclusions: c-Myc nuclear immunoreactivity is a predictor of poorer response to radiotherapy and poorer disease free status in stage II B and III B carcinoma of the cervix.

c-Myc expression; Carcinoma cervix; Prognosis

[1] Das B. C., Gopalkrishna V., Suresh H., Sanjay K.: "Cancer of uterine cervix and human papilloma virus infection". Curr. Science, 2000, 78, 52.

[2] Dang C. V.: "c-Myc oncoprotein function". Biochem Biophys Acta., 1991, 1072, 103.

[3] Ryan K., Birnie G.: "myc oncogenes - the enigmatic family". Biochem. J., 1996, 314, 713.

[4] Jones T. R., Cole M. D.: "Rapid cytoplasmic turnover of c-Myc in RNA- requirements of the 3'untranslated sequences". Mot. Cell. Biol., 1987, 7, 4513.

[5] Henrikkson M., Luscher B.: "Proteins of the myc network - essential regulators of cell growth and differentiation". Adv. in Cancer Res., 1996, 68, 108.

[6] Schrier P. T., Peltenburg L. T. C.: "Relationship between Myc oncogene activation and MHC class I expression". Adv. in Cancer Res., 1993, 60, 181.

[7] Williams A., Piris J., Wyllie A.: "Immunohistochemical demonstration of altered intracellular localization of the c-Myc oncogene product in human colorectal neoplasms". J. of Pathology, 1990, 160, 287.

[8] Riou G., Barrois M., Le M. G. et al.: "c-Myc proto oncogene expression and prognosis in early carcinoma of the uterine cervix". Lancet, 1987, 1, 761.

[9] Riou G., Monique G., Le M. F., Bourhis G. 0.: "Human papilloma virus negative status and c-Myc overexpression: Independent prognostic indicators of distant metastasis for early stage invasive cancers". J. Natl. Cancer Inst., 1992, 84 (19), 1525.

[10] Riou G. F., Bourhis J., Le M. G.: "The c-Myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in the early stages of the cancer". Anrticancer res., 1990, 5 (A), 1225.

[11] Bourhis J., Le M. G., Barrois A., Gerbaulet D., Jeannel P., Duvillard V. et al.: "Prognostic value of c-Myc proto-oncogene overexpression in early invasive carcinoma of cervix". J. of Clinical Oncol., 1990, 8, 1789.

[12] Nair S. A., Nair M. B., Jayaprakash P. G., Rajalekshmy T. N., Nair M. K., Pillai M. R.: "Ras and c-Myc oncoproteins during tumour progression in the uterine cervix". Tumori, 1998, 84 (5), 583.

[13] Tanimoto H., Nagai N., F ujimoto H., Ohta S., Oharna K.: "Molecular biological study on the overexpression of c-Myc gene in uterine cervical carcinomas". Nippon Sanka Fujinka Gakkai Zasshi, 1992, 44 (5), 566.

[14] Ocadiz K., Sauceda R., Miguel C., Graef A., Gariglio P.: "High correlation between molecular alterations of the c-Myc oncogene and carcinoma of uterine cervix". Cancer res., 1987, 47, 4173.

[15] Sowani A., Ong G., Dishche S., Quinn C., White J., Soutter P. et al.: "c-Myc oncogene expression and clinical outcome in carcinoma of the cervix". Mo/. cell. Probes., 1989, 2, 117.

[16] Sato S., Itok K.: "Expression of c-Myc, EGF R, c-erb82 in cervical adenocarcinoma". Tohoku J. Exp. Med., 1991, 165 (2), 137.

[17] Dellas A., Schultheiss E., Leivas M. R., Moch H., Torhorst J.: "Association of p27 kip l , Cyclin E. and c-Myc expression with progression and prognosis in HPV positive cervical neoplasms" Anticancer Res., 1998, 18 (6A), 3991.